---
figid: PMC6109055__41467_2018_5966_Fig6_HTML
figtitle: 'Model: SIRT6 levels regulate resistance or sensitivity to MAPKi'
organisms:
- Homo sapiens
- Mus musculus
- Diaporthe sclerotioides
- Equus caballus
- Calloplesiops altivelis
pmcid: PMC6109055
filename: 41467_2018_5966_Fig6_HTML.jpg
figlink: /pmc/articles/PMC6109055/figure/Fig6/
number: F6
caption: 'Model: SIRT6 levels regulate resistance or sensitivity to MAPKi. (Top) Under
  baseline conditions, SIRT6 deacetylates H3K56ac at the IGFBP2 locus to maintain
  low expression levels and low IGF-1R/AKT pathway signaling, impairing cell survival
  in the presence of MAPKi. (Middle) In the context of SIRT6 haploinsufficiency, IGFBP2
  expression is enhanced via increased chromatin accessibility and H3K56 acetylation
  at the IGFBP2 locus. Activation of the IGF-1 receptor (IGF-1R) and downstream AKT
  signaling allows melanoma cells to persist in the presence of MAPKi. (Bottom) SIRT6
  depletion triggers significant chromatin reorganization reflected by increased open
  chromatin and H3K56ac at these sites, coupled to DNA damage accumulation. This potential
  for genomic instability increases the sensitivity to MAPKi'
papertitle: SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to
  MAPK inhibitors via IGF signalling.
reftext: Thomas Strub, et al. Nat Commun. 2018;9:3440.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8329722
figid_alias: PMC6109055__F6
figtype: Figure
organisms_ner:
- Homo sapiens
- Equus caballus
- Mus musculus
redirect_from: /figures/PMC6109055__F6
ndex: af8ab63b-de98-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6109055__41467_2018_5966_Fig6_HTML.html
  '@type': Dataset
  description: 'Model: SIRT6 levels regulate resistance or sensitivity to MAPKi. (Top)
    Under baseline conditions, SIRT6 deacetylates H3K56ac at the IGFBP2 locus to maintain
    low expression levels and low IGF-1R/AKT pathway signaling, impairing cell survival
    in the presence of MAPKi. (Middle) In the context of SIRT6 haploinsufficiency,
    IGFBP2 expression is enhanced via increased chromatin accessibility and H3K56
    acetylation at the IGFBP2 locus. Activation of the IGF-1 receptor (IGF-1R) and
    downstream AKT signaling allows melanoma cells to persist in the presence of MAPKi.
    (Bottom) SIRT6 depletion triggers significant chromatin reorganization reflected
    by increased open chromatin and H3K56ac at these sites, coupled to DNA damage
    accumulation. This potential for genomic instability increases the sensitivity
    to MAPKi'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - SIRT6
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - IGFBP2
  - AKT1
  - AKT2
  - AKT3
  - TF
  - IGF1R
  - ac
  - Sirt6
  - Igfbp2
  - Akt1
  - Igf1r
  - Ac
  - linsitinib
---
